Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy children aged 12-23 months~* Written informed consent~Exclusion Criteria:~* History of documented HIV~* Known or suspected impairment of immunologic function~* History of serious chronic disease~* Received any JE vaccine prior to enrollment

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- vero cell-derived JE vaccine (Type: EXPERIMENTAL): vero cell-derived vaccine group
- Mouse brain-derived JE vaccine (Type: ACTIVE_COMPARATOR): Mouse brain-derived JE vaccine group

Based on this trial design, predict the completion outcome and termination type (if applicable).